Key Highlights

● Neurogene shares moved up about 12.71% on October 28, 2026.

● Gene therapy data for Rett syndrome took the stage at a medical conference in Hamburg.

● The move stood apart from the broader market's modest session gain.

● The stock closed at $30.42 on October 28, 2026.

Neurogene (NASDAQ:NGNE), a clinical-stage company developing genetic medicines for rare neurological diseases, rallied on Wednesday. The shares closed at $30.42, up 12.71%. The move coincided with the company's scheduled presentations on its lead programme, NGN-401 for Rett syndrome, at the European Society of Gene and Cell Therapy's 33rd Annual Congress in Hamburg. No separate press release from Neurogene dated October 27 or 28 was found, so the presentations are the most relevant company event on the day, though they were announced in advance.

Company Context

On October 20, Neurogene said it would present preclinical and clinical data at the congress, which runs from October 27 to 30. The schedule included an invited talk on October 28 titled "Self-regulating gene therapy for Rett syndrome," along with two posters that afternoon. One poster compared two microRNA-regulated gene therapies in a mosaic Rett model, and the other addressed intracerebroventricular administration, a method of delivering therapy into the fluid-filled spaces of the brain. A further poster on October 29 was set to cover expression kinetics and the clinical onset of benefit for NGN-401. The company said the presentations would include new preclinical data on how quickly single-stranded AAV produces MECP2 expression and early time-to-response observations from its Phase 1/2 trial.

Session Backdrop

The stock had been weaker in the days before the meeting. It closed at $23.55 on October 23, so Wednesday's finish represents a substantial recovery over a short span. Since no new numerical data from the talks were verified for this report, it is not possible to say which details investors reacted to, only that the gain came on the day the programme was showcased to an audience of gene therapy researchers and industry participants. Broader strength in biotech shares may also have contributed.

Rett syndrome is a rare neurodevelopmental disorder, seen mostly in girls, caused by mutations in the MECP2 gene. A central challenge for gene therapy in Rett is that too much MECP2 can be harmful as well as too little. Neurogene's EXACT technology is designed to regulate expression of the transgene within individual cells, which is why the company's presentations emphasise self-regulation. NGN-401 is a one-time AAV9 gene therapy and holds FDA Breakthrough Therapy, RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease designations, along with designations from European and UK regulators.

The programme has reached an advanced stage. In June, Neurogene said it had completed dosing in Embolden, its registrational trial, treating 25 participants at the 1E15 vg dose. The primary analysis will come after the first 24 participants complete 12 months of follow-up, with topline data expected in the second half of 2027. The company has said the dose was generally well tolerated. Financially, Neurogene reported cash and short-term investments of $225.4 million at June 30, or about $360.2 million on a pro forma basis after a $125 million public offering in July, which it expects to fund operations into the first quarter of 2029.

The rally fitted a broader pattern on Wednesday, when biotech stocks moved heavily on trial and financing news, and other gene therapy and gene editing names also appeared among the day's gainers. The overall market was subdued, with the S&P 500 up 0.3% at a record close, the Federal Reserve holding rates at 3.75% to 4.00%, and the 10-year Treasury yield hovering around 5%.

What This Move Means for Neurogene

Investors are likely to watch for the remaining congress presentation, any further detail on Phase 1/2 follow-up data, the progress of Embolden toward its primary analysis, and the company's planning for a potential biologics licence application, which it has said would depend on trial results.